BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sage Medical Begins Series B Fundraising


10/20/2006 9:19:43 AM

PLYMOUTH, Minn.--(BUSINESS WIRE)--Sage Medical Technologies, Inc (Sage Medical) presented at the In3 East Investor Conference yesterday in Boston, MA. Sage Medical is an early stage medical device company developing its core endovascular technology to address two deficits of the aorta. The company is completing animal studies with a plan to initiate human feasibility trials in the first quarter of 2008.

"We are delighted with the rapid progress of our research & development team in producing a functional prototype and its evaluation in animals. The timeline from product sketch to implant has been an impressive six months. Augmenting this is enthusiastic guidance from key opinion leaders in both the cardiology and vascular surgery communities," said Jagi Gill, Chief Executive Officer.

The first program of the company is focused on aortic dissection, a condition which develops acutely as a tear in the aortic wall leading to rapid blood loss. Current surgical and medical treatments have a mortality rate of over 30 %. A minimally invasive approach designed specifically to treat aortic dissections offers a much needed solution to this catastrophic disease. Over 35,000 patients per year in the US would be candidates for use of the Sage Medical system.

The core technology is also being developed to provide a catheter-based solution to entrap plaque which resides in the aortic arch. Aortic plaque has been documented to contribute to 15-25 % of all ischemic strokes. Much like the growth in carotid artery stenting to reduce the incidence of stroke for appropriate patients, the safe deployment of the Sage Medical plaque-entrapping stent should reduce the risk of stroke in over 130,000 persons in the US who annually present with aortic arch plaque.

Sage Medical is actively raising funds for its Series B financing. This will permit for the completion of animal work and initial human studies for both clinical programs.

About Sage Medical Technologies, Inc

Sage Medical has been in operations since January 2006 in its facility outside of Minneapolis, MN. The company's proprietary and patent pending technologies combine an ultra-flexible nitinol stent, macro-porous covering to promote vessel healing along with a unique user-friendly catheter delivery system. While conventional stent-grafts do not permit for accurate deployment around the aortic arch, the Sage Medical system is designed to enable the endovascular surgeon to do so in a percutaneous manner.

More information regarding Sage Medical can be found by calling the company at 763-746-0240 or by email at jgill@sagemedinc.com.

Contact: Sage Medical Jagi Gill, Chief Executive Officer, 763-746-0240 jgill@sagemedinc.com

Source: Sage Medical

>>> Discuss This Story



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES